-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The 2021 National Medical Insurance Drug List Negotiations are already on the line.
It is reported that the new round of medical insurance negotiations is currently scheduled for early November
.
Institutional data shows that there are about 20 domestically-made innovative drugs that will be negotiated for the first time, including PARP inhibitors, BTK inhibitors, ALK inhibitors, ADC drugs (antibody-coupled drugs), CAR-T therapy (chimeric antigens) Receptor T cell immunotherapy), etc.
, involving many listed pharmaceutical companies such as BeiGene, Rongchang Biotechnology, Betta Pharmaceuticals, Hengrui Pharmaceuticals, and Zejing Pharmaceuticals
.
At present, as a new round of medical insurance negotiations is about to start, major listed pharmaceutical companies are actively preparing for the battle
.
For example, BeiGene’s three quarterly reports disclosed on November 5 showed that the company is preparing for the upcoming medical insurance negotiations.
Eligible products include the newly added first-line treatment of non-squamous non-small cell lung cancer (NSCLC) and the first-line treatment of squamous cell carcinoma.
For non-small cell lung cancer (NSCLC) and second-line or third-line treatment for hepatocellular carcinoma (HCC) indications Baizian, Wahrenheit macroglobulinemia (WM) indications Baiyueze, and previous treatments At least second-line chemotherapy, advanced ovarian cancer, fallopian tube cancer or primary peritoneal cancer patients with germline BRCA (gBRCA) mutations
.
On November 4, Rongchang Biotech stated in the disclosed prospectus that the company’s core product, tetaxacept, was used for the treatment of systemic lupus erythematosus, and vedicitumumab was used for the treatment of gastric cancer in March 2021 and June 2021, respectively.
It was approved to be listed in China with conditions on May.
The company is actively preparing relevant materials for participating in medical insurance negotiations, with a view to rapidly expanding product sales channels in a short period of time, and effectively and quickly promoting product sales
.
Betta Pharmaceuticals also stated in the record of investor relations activities disclosed on November 2 that at the time of a new round of medical insurance negotiations, the company is also actively docking the access work of Kemena and Bemena
.
In addition to domestic pharmaceutical companies, the enthusiasm of multinational pharmaceutical companies for medical insurance negotiations has also increased significantly.
This year, many multinational pharmaceutical companies including Pfizer, Janssen, Eli Lilly, Amgen, Servier, and other multinational pharmaceutical companies have actively reduced prices of related products.
Industry analysts believe that it may be a preparation for entering medical insurance
.
For example, in July of this year, Pfizer’s clofenac soft capsules took the initiative to cut prices on local platforms, from 64,100 yuan per box to 24,650 yuan, a drop of more than 61%; Janssen’s 400mg/20ml daratumumab, The price dropped from 19710 yuan to 8512 yuan, a decrease of 56.
8%; for another example, in March this year, Sanofi’s Aliximab voluntarily applied for a price reduction in Liaoning Province.
The online price was adjusted from 1888 yuan to 998 yuan, which was about 47%
.
The industry pointed out that the current medical insurance negotiations have become an important catalyst for the volume of innovative drugs
.
Judging from the experience of the previous rounds of medical insurance negotiations, most innovative drugs have achieved substantial growth in the amount in a short period of time after entering the medical insurance through price-for-volume exchange
.
According to the data from the "Blue Book on the Progress and Effectiveness of Medical Insurance Drug Administration Reform", the amount of negotiated drugs in 2018 showed rapid growth from the fourth quarter of the year to the fourth quarter of 2019, and the single-quarter high year-on-year increase reached 1582%; the negotiated drugs in 2019 , The consumption in the third and fourth quarters of 2020 increased by 657.
6% and 768.
6% year-on-year
.
In addition, after innovative drugs enter the medical insurance, the difficulty of entering the hospital can also be alleviated, and rapid penetration of hospitals and pharmacies can be achieved
.
Therefore, for innovative drug companies, it will be an opportunity to increase volume
.
It is reported that the new round of medical insurance negotiations is currently scheduled for early November
.
Institutional data shows that there are about 20 domestically-made innovative drugs that will be negotiated for the first time, including PARP inhibitors, BTK inhibitors, ALK inhibitors, ADC drugs (antibody-coupled drugs), CAR-T therapy (chimeric antigens) Receptor T cell immunotherapy), etc.
, involving many listed pharmaceutical companies such as BeiGene, Rongchang Biotechnology, Betta Pharmaceuticals, Hengrui Pharmaceuticals, and Zejing Pharmaceuticals
.
At present, as a new round of medical insurance negotiations is about to start, major listed pharmaceutical companies are actively preparing for the battle
.
For example, BeiGene’s three quarterly reports disclosed on November 5 showed that the company is preparing for the upcoming medical insurance negotiations.
Eligible products include the newly added first-line treatment of non-squamous non-small cell lung cancer (NSCLC) and the first-line treatment of squamous cell carcinoma.
For non-small cell lung cancer (NSCLC) and second-line or third-line treatment for hepatocellular carcinoma (HCC) indications Baizian, Wahrenheit macroglobulinemia (WM) indications Baiyueze, and previous treatments At least second-line chemotherapy, advanced ovarian cancer, fallopian tube cancer or primary peritoneal cancer patients with germline BRCA (gBRCA) mutations
.
On November 4, Rongchang Biotech stated in the disclosed prospectus that the company’s core product, tetaxacept, was used for the treatment of systemic lupus erythematosus, and vedicitumumab was used for the treatment of gastric cancer in March 2021 and June 2021, respectively.
It was approved to be listed in China with conditions on May.
The company is actively preparing relevant materials for participating in medical insurance negotiations, with a view to rapidly expanding product sales channels in a short period of time, and effectively and quickly promoting product sales
.
Betta Pharmaceuticals also stated in the record of investor relations activities disclosed on November 2 that at the time of a new round of medical insurance negotiations, the company is also actively docking the access work of Kemena and Bemena
.
In addition to domestic pharmaceutical companies, the enthusiasm of multinational pharmaceutical companies for medical insurance negotiations has also increased significantly.
This year, many multinational pharmaceutical companies including Pfizer, Janssen, Eli Lilly, Amgen, Servier, and other multinational pharmaceutical companies have actively reduced prices of related products.
Industry analysts believe that it may be a preparation for entering medical insurance
.
For example, in July of this year, Pfizer’s clofenac soft capsules took the initiative to cut prices on local platforms, from 64,100 yuan per box to 24,650 yuan, a drop of more than 61%; Janssen’s 400mg/20ml daratumumab, The price dropped from 19710 yuan to 8512 yuan, a decrease of 56.
8%; for another example, in March this year, Sanofi’s Aliximab voluntarily applied for a price reduction in Liaoning Province.
The online price was adjusted from 1888 yuan to 998 yuan, which was about 47%
.
The industry pointed out that the current medical insurance negotiations have become an important catalyst for the volume of innovative drugs
.
Judging from the experience of the previous rounds of medical insurance negotiations, most innovative drugs have achieved substantial growth in the amount in a short period of time after entering the medical insurance through price-for-volume exchange
.
According to the data from the "Blue Book on the Progress and Effectiveness of Medical Insurance Drug Administration Reform", the amount of negotiated drugs in 2018 showed rapid growth from the fourth quarter of the year to the fourth quarter of 2019, and the single-quarter high year-on-year increase reached 1582%; the negotiated drugs in 2019 , The consumption in the third and fourth quarters of 2020 increased by 657.
6% and 768.
6% year-on-year
.
In addition, after innovative drugs enter the medical insurance, the difficulty of entering the hospital can also be alleviated, and rapid penetration of hospitals and pharmacies can be achieved
.
Therefore, for innovative drug companies, it will be an opportunity to increase volume
.
